C12N 2760/16134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/16134 (Use of virus or viral component as vaccine) appears on 1,554 US grants and 2,564 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,554
- Published applications
- 2,564
- Assignees
- 989
- Inventors
- 3,921
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 8 | 0 |
| 1977 | 2 | 0 |
| 1978 | 3 | 0 |
| 1979 | 3 | 0 |
| 1980 | 5 | 0 |
| 1981 | 2 | 0 |
| 1982 | 3 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 6 | 0 |
| 1986 | 2 | 0 |
| 1987 | 5 | 0 |
| 1988 | 3 | 0 |
| 1989 | 3 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 15 | 0 |
| 1998 | 24 | 0 |
| 1999 | 16 | 0 |
| 2000 | 12 | 0 |
| 2001 | 18 | 6 |
| 2002 | 14 | 21 |
| 2003 | 15 | 35 |
| 2004 | 14 | 55 |
| 2005 | 12 | 38 |
| 2006 | 13 | 49 |
| 2007 | 15 | 70 |
| 2008 | 21 | 70 |
| 2009 | 42 | 103 |
| 2010 | 25 | 115 |
| 2011 | 43 | 124 |
| 2012 | 45 | 132 |
| 2013 | 61 | 126 |
| 2014 | 75 | 131 |
| 2015 | 89 | 114 |
| 2016 | 95 | 133 |
| 2017 | 97 | 143 |
| 2018 | 111 | 130 |
| 2019 | 115 | 132 |
| 2020 | 94 | 112 |
| 2021 | 83 | 99 |
| 2022 | 72 | 133 |
| 2023 | 64 | 127 |
| 2024 | 75 | 167 |
| 2025 | 77 | 116 |
| 2026 | 43 | 83 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Virus-like particles containing CST1 protein and toxoplasma vaccine using same1 Sep 2026US 12,721,886 B2University-Industry Cooperation Group of Kyung Hee University
- Coronavirus and influenza compositions and methods for using them25 Aug 2026US 12,714,744 B2
- Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)25 Aug 2026US 12,714,745 B2Baylor Research Institute
- Method for prevention and treatment of viral disease25 Aug 2026US 12,714,746 B2Morehouse School of Medicine
- Influenza virus encoding a truncated NS1 protein and a SARS-CoV receptor binding domain18 Aug 2026US 12,708,663 B2Vivaldi Biosciences Inc.
- Influenza ehead immunogens1 Oct 2026US 2026/0295029 A1The Scripps Research Institute
- Universal avian flu vaccine (aiv)1 Oct 2026US 2026/0297137 A1DEI Biopharma
- Influenza virus vaccines24 Sep 2026US 2026/0284174 A1Glaxosmithkline Biologicals SA
- Immunogenic compositions against influenza and rsv17 Sep 2026US 2026/0273040 A1Pfizer Inc.
- Broadly reactive viral antigens as immunogens, compositions and methods of use thereof17 Sep 2026US 2026/0273041 A1University of Georgia Research Foundation, Inc.
Most cited
By later US patents
- Method for immunizing animals with synthetically modified vaccinia virus240US 4,722,848 AHealth Research, Inc. · 1988
- Nucleic acid vaccines165US 9,872,900 B2ModernaTX, Inc. · 2018
- Liposome particle containing viral or bacterial antigenic subunit152US 4,235,877 AMerck & Co., Inc. · 1980
- Viral liposome particle151US 4,261,975 AMerck & Co., Inc. · 1981
- Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein146US 5,858,368 AProtein Sciences Corporation · 1999